CheckMate 722: faasi 3, randomoitu, n=294. EGFR -mut. keuhkosyöpä, joka edennyt TKI:n jälkeen. Nivolumabi + platinadubletti vs. platinadubletti.

PFS 5.6 kk vs. 5.4 kk, HR 0.75 [95% CI, 0.56 – 1.00]; P = .0528) ei eroa.

ORR 31.3 % vs. 26.7 %.

Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722